RapidNIPT is a dedicated NIPT test brand offered by the Genoks Genetic Diseases Assessment Center. All analyses are performed using high-technology systems within a fully automated laboratory infrastructure in Ankara. The process is conducted in accordance with high sensitivity and reliability standards, using methods that minimize human intervention.

RapidNIPT makes the genetic evaluation process patient-focused, fast, and practical. Test results are assessed by experienced medical genetics specialists and are presented to families together with professional genetic counseling.

How Is the RapidNIPT Test Performed?

The RapidNIPT test can be applied from the 10th week of pregnancy onward. The procedure is quite simple:

• A single tube of blood is collected from the expectant mother’s arm, just like a routine blood test.
• cfDNA (cell-free DNA) present in the blood sample is analyzed. cfDNA is genetic material that passes from the placenta into the mother’s bloodstream during pregnancy and provides information about the fetus.
• cfDNA is examined using advanced molecular analysis techniques.

Through this approach, fetal genetic data can be evaluated and a risk analysis for chromosomal abnormalities can be performed.

Down Syndrome and NIPT

The NIPT test is a reliable method particularly used in the assessment of common chromosomal abnormalities such as Down syndrome (Trisomy 21). Down syndrome results from the presence of an extra copy of chromosome 21 and is one of the most frequently observed chromosomal conditions during pregnancy.

Within the scope of screening for Down syndrome risk, RapidNIPT provides families with valuable information. In addition, evaluations can also be performed for other chromosomal abnormalities such as Trisomy 18 and Trisomy 13.

RapidNIPT and cfDNA Analysis

The focus of the RapidNIPT test is cfDNA found in the mother’s blood. cfDNA naturally circulates during pregnancy and reflects the genetic structure of the fetus. Thanks to this modern approach, risk assessment is performed without any invasive procedures, ensuring a safe process for both the mother and the baby.

Advantages of RapidNIPT

• Non-invasive method: Only a blood sample is required.
• Early applicability: Can be performed from the 10th week of pregnancy.
• Broad screening scope: Down syndrome and other chromosomal abnormalities can be evaluated.
• Fast results: Risk assessment can be completed within a short time.
• Expert support: Results are interpreted by physician medical genetics specialists.